Catalyst

Slingshot members are tracking this event:

Flamel Technologies(FLML) expects PDUFA decision from FDA for an unapproved marketed drug

Source Link:
http://seekingalpha.com/article/3387765-flamel-technologies-flml-ceo-mike-anderson-on-q2-2015-results-earnings-call-transcript?page=2

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
FLML
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Flamel submitted an NDA for the drug in the second quarter of 2015, and they expect the standard 10 month PDUFA date. The company expects a $70 million market size for this drug.
http://seekingalpha....
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
May 02, 2016
Occurred Source:
http://www.flamel.com/wp-content/uploads/2016/05/Flamel-Receives-Akovaz-Approval-20160502.pdf
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Pdufa, Mystery Products
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.